Phase II study of S-1 plus amrubicin as the 2nd-line treatment for non-small cell lung cancer without EGFR mutatio
Phase 2
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000003653
- Lead Sponsor
- Kanagawa Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1)patients previously treated with amrubicin and 5-FU derivative drugs 2)pleural effusion(eligible for difficult puncture case or cytologically negative and clinically ignorable case) 3)evident pericardial effusion 4)serious complications below uncontrollable angina pectoris, myocardial infarction within 3 months or heart failure uncontrollable diabetes uncontrollable hypertension severe infection 5)pulmonary fibrosis or interstitial pneumonitis evident 6)HB and HC virus carrier 7)now pregnant or lactation 8)difficult to perform or continue of this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method